Hainan Honz Pharmaceutical Co (300086) - Total Liabilities
Based on the latest financial reports, Hainan Honz Pharmaceutical Co (300086) has total liabilities worth CN¥828.17 Million CNY (≈ $121.19 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hainan Honz Pharmaceutical Co - Total Liabilities Trend (2007–2025)
This chart illustrates how Hainan Honz Pharmaceutical Co's total liabilities have evolved over time, based on quarterly financial data. See Hainan Honz Pharmaceutical Co (300086) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Hainan Honz Pharmaceutical Co Competitors by Total Liabilities
The table below lists competitors of Hainan Honz Pharmaceutical Co ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Feedback Technology
TWO:8091
|
Taiwan | NT$1.34 Billion |
|
Cogobuy Group
F:7C3
|
Germany | €6.18 Billion |
|
Costamare Bulkers Holdings Limited
NYSE:CMDB
|
USA | $309.79 Million |
|
HCM II Acquisition Corp
NASDAQ:HOND
|
USA | $15.00 Million |
|
Binggrae
KO:005180
|
Korea | ₩325.15 Billion |
|
Shenzhen Mingdiao Decoration Co Ltd
SHE:002830
|
China | CN¥663.45 Million |
|
Norske Skog Asa
OL:NSKOG
|
Norway | Nkr8.29 Billion |
|
Zhejiang Realsun Chemical Co. Ltd.
SHE:301212
|
China | CN¥379.35 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down Hainan Honz Pharmaceutical Co's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Hainan Honz Pharmaceutical Co stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.93 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hainan Honz Pharmaceutical Co's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hainan Honz Pharmaceutical Co (2007–2025)
The table below shows the annual total liabilities of Hainan Honz Pharmaceutical Co from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥869.79 Million ≈ $127.28 Million |
+7.31% |
| 2024-12-31 | CN¥810.53 Million ≈ $118.61 Million |
+2.91% |
| 2023-12-31 | CN¥787.60 Million ≈ $115.25 Million |
-15.58% |
| 2022-12-31 | CN¥932.96 Million ≈ $136.52 Million |
+3.07% |
| 2021-12-31 | CN¥905.14 Million ≈ $132.45 Million |
-10.55% |
| 2020-12-31 | CN¥1.01 Billion ≈ $148.08 Million |
+70.76% |
| 2019-12-31 | CN¥592.59 Million ≈ $86.72 Million |
+12.47% |
| 2018-12-31 | CN¥526.90 Million ≈ $77.10 Million |
+67.10% |
| 2017-12-31 | CN¥315.31 Million ≈ $46.14 Million |
-0.48% |
| 2016-12-31 | CN¥316.83 Million ≈ $46.36 Million |
+27.63% |
| 2015-12-31 | CN¥248.25 Million ≈ $36.33 Million |
+102.67% |
| 2014-12-31 | CN¥122.49 Million ≈ $17.92 Million |
+29.80% |
| 2013-12-31 | CN¥94.36 Million ≈ $13.81 Million |
-0.70% |
| 2012-12-31 | CN¥95.02 Million ≈ $13.91 Million |
-14.22% |
| 2011-12-31 | CN¥110.77 Million ≈ $16.21 Million |
+45.73% |
| 2010-12-31 | CN¥76.01 Million ≈ $11.12 Million |
+41.83% |
| 2009-12-31 | CN¥53.60 Million ≈ $7.84 Million |
-4.17% |
| 2008-12-31 | CN¥55.93 Million ≈ $8.18 Million |
+117.75% |
| 2007-12-31 | CN¥25.68 Million ≈ $3.76 Million |
-- |
About Hainan Honz Pharmaceutical Co
Honz Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and sales of pediatric medicines in China. The company offers medicines for children and adults in the areas of anti-anaphylaxis, antidiarrheal and digestive, relieving cough, anti-flu, antipyretic, anti-infection, anti-fungal, antipyretic-analgesic, and endocrine; and medical, disposable, and protective face ma… Read more